LifeSci Partners Podcast
By LifeSci Partners.com
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by LifeSci Partners.com
Category: Life Sciences
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 74
Description
This podcast series, sponsored by LifeSci Partners, brings the listener right into the mindset, and motivations of some of the top players in the healthcare biotechnology industry.
| Episode | Date |
|---|---|
|
Leveraging AI and ML in Drug R&D: Current and Future Impacts to the Life Sciences Industry
|
Oct 03, 2023 |
|
LifeSci Search Podcast: Episode #1
|
Mar 17, 2023 |
|
Regenerative Medicine from Humacyte: Off-the-Shelf, Human-Sourced Acellular Vessels for Traumatic Wound Repair
|
Feb 10, 2023 |
|
A Brief Chat with Erez Raphael, CEO of DarioHealth
|
Jan 06, 2023 |
|
Onconova – Developing Best-in-class Anti-cancer Agents with Multi-faceted MOAs
|
Jan 05, 2023 |
|
A Brief Chat with Dror Bashan, President & CEO of Protalix Biotherapeutics, Inc.
|
Jan 04, 2023 |
|
A Brief Chat with Martin Welschof, CEO of BioInvent
|
Jan 03, 2023 |
|
A Brief Chat with Raphi Levy, CFO of Alpha Tau Medical Ltd.
|
Dec 29, 2022 |
|
A Brief Chat with Amir London, CEO of Kamada Ltd.
|
Dec 28, 2022 |
|
A Brief Chat with Rob Etherington, President & CEO of Clene, Inc.
|
Dec 27, 2022 |
|
Helping the Body Help Itself with EscharEx: The Next Generation Wound-Care Therapeutic from MediWound
|
Dec 16, 2022 |
|
A Promising New Immune Checkpoint from Sensei Bio: VISTA
|
Dec 13, 2022 |
|
Turning Amino Acids into Drugs: A Novel Platform from Axcella Health
|
Dec 08, 2022 |
|
Lipocine Inc’s Formulation for Success: Oral Agents for CNS Disorders
|
Nov 17, 2022 |
|
89bio Aims to Tame NASH and Severe Hypertriglyceridemia (SHTG) with Lead Asset Pegozafermin
|
Nov 11, 2022 |
|
De-Risked Oncology Targets with Assets from Checkpoint Therapeutics
|
Nov 04, 2022 |
|
Deep Transcranial Magnetic Stimulation (Deep TMS™): BrainsWay’s Innovative and Non-Invasive Therapy for Major Depressive Disorder, Anxious Depression, OCD, and Smoking Addiction
|
Oct 20, 2022 |
|
An Oncology Update on CDK 2/9 Inhibition: Cyclacel Pharmaceuticals
|
Sep 29, 2022 |
|
Oncology on the Move—Artios: Financing Considerations for an Early Biotech
|
Sep 19, 2022 |
|
Fire Up the Immune System to Lead the Charge Against Cancer: Alligator Bioscience
|
Sep 15, 2022 |
|
Esperion Therapeutics: A Small Company with a Big Heart
|
Aug 31, 2022 |
|
Patient-centric, Physician-managed healthcare centers that Payers love: P3 Health Partners
|
Aug 22, 2022 |
|
Two Oncology Assets in the Clinic and a sought-after Discovery Platform: Ryvu Therapeutics
|
Aug 04, 2022 |
|
Advances in gene therapy delivery: a non-viral pDNA platform that harnesses the power of IL-10
|
Jul 29, 2022 |
|
A Pioneer of PARP Inhibition has a New DNA Damage Repair (DDR) Platform
|
Jul 26, 2022 |
|
Teclison’s cancer immunotherapy-enhancer, TEC-001, shows efficacy in all-cause hepatic tumors
|
Jul 15, 2022 |
|
iBreathe it in: Inhalable drug delivery with the iSPERSE platform, from Pulmatrix
|
Jul 11, 2022 |
|
P53 Reactivation via MDM2 Inhibition with Milademetan: Phase 3 Data in 1H 2023 (Rain Therapeutics)
|
Jul 11, 2022 |
|
An anti-PD-L1 Antibody Given Subcutaneously: Envafolimab, by Tracon Pharma
|
Jul 01, 2022 |
|
Two conditions, one drug: working to relieve chronic cough in IPF, and debilitating itch in prurigo nodularis with the opioid-receptor-targeting drug, HADUVIO
|
Jun 27, 2022 |
|
Special Delivery Platforms: pH-activated and STING activating polymeric micelles from OncoNano Medicine
|
Jun 23, 2022 |
|
Phase II POC for Immutep’s LAG-3 drug, eftilagimod alpha: ASCO data, and an introduction to CEO Marc Voigt
|
Jun 22, 2022 |
|
Inducing Immune Tolerance in Autoimmunity, Gene Therapy, and Beyond: The ImmTOR® Platform, from Selecta Biosciences
|
Jun 17, 2022 |
|
Dosing more than Skin Deep: A Transdermal Drug Delivery Platform from Dyve Biosciences
|
Jun 10, 2022 |
|
Location, Location, Location: Delivering Your IO Asset Directly to the Lymph Node with Amphiphile
|
May 13, 2022 |
|
Making sure there’s not a dry eye in the house with Tyrvaya®, from Oyster Point Pharma
|
May 06, 2022 |
|
The sweet spot (and the market) between the adaptive & innate immune response: Allogeneic Natural Killer T cells (NKT) from Athenex
|
Apr 22, 2022 |
|
A Rare (Disease) Opportunity: Amolyt Pharma – Targeting Orphan Diseases of the Endocrine System
|
Apr 14, 2022 |
|
A clinical-stage biotech company developing a targeted oral small molecule for synergistic combinations with SOC -that's Cardiff Oncology.
|
Mar 25, 2022 |
|
Today’s Oncology Play: Global Reach, Clinical Stage Assets, and a Revenue Stream – Antengene
|
Mar 18, 2022 |
|
Dyadic International: Helping to produce biologic vaccines and drugs rapidly, in large quantities and at low cost for a global population.
|
Mar 10, 2022 |
|
Differentiated Delivery with DPX® - a Versatile Technology for Immuno-Oncology by IMV Inc.
|
Mar 03, 2022 |
|
Developing Drugs for Rare Diseases: Pointers and Pitfalls
|
Feb 28, 2022 |
|
Targeting Cancer and Fibrosis. Galecto aims to help patients with their first-in-class, small molecule drugs in clinical development
|
Feb 24, 2022 |
|
Mapping Neoantigens in Cancer with Genocea’s ATLAS: What to Include, and What to Avoid in Your Cancer Therapy
|
Feb 18, 2022 |
|
Every tumor is a deadly frontier, and to survive it you need a personalized, therapeutic path forward. Enter the AI-centric guidance of Evaxion’s, PIONEER
|
Feb 11, 2022 |
|
Water, Water, Everywhere – Innovations in Treating Diuretic-Resistant Fluid Overload: Sequana Medical
|
Jan 21, 2022 |
|
Modulation of NMDA Receptors for Pain and CNS Disorders: The Middle Way – that’s Aptinyx
|
Jan 14, 2022 |
|
Immatics: Engineering the Right T Cell Receptor for Shared Tumor-Associated Targets
|
Jan 06, 2022 |
|
Captor Therapeutics: Top Grades for Degrading Pathologic Proteins in Oncology and Autoimmune Disease: Captor Therapeutics
|
Dec 17, 2021 |
|
Discovery Platform for Small Molecule mRNA Drugs like no other: mRNA Lightning, from Anima Biotech
|
Dec 10, 2021 |
|
Seeing clearly where the sun don’t shine: A game-changing technology in GI endoscopy from Motus GI
|
Dec 03, 2021 |
|
GBS Inc: A Saliva Test for Diabetes Monitoring: An inside look at the Glucose Biosensor Technology
|
Nov 15, 2021 |
|
Lean and mean, outsourcing oncology machine: Anixa Biosciences, Inc.
|
Nov 12, 2021 |
|
NOXXON: Targeting the Chemokines of the TME to enhance Cancer Therapies
|
Nov 05, 2021 |
|
Femasys Inc: Putting the Focus on Women’s Reproductive Health
|
Oct 28, 2021 |
|
To Find the best Antigens for Cancer, or COVID, Gritstone bio has the EDGE™
|
Oct 22, 2021 |
|
Vincerx Pharma: From Pharmacyclics to Cyclins – The Will and the Way
|
Oct 08, 2021 |
|
Repairing Organ Damage – Angion Biomedica
|
Sep 29, 2021 |
|
Experience, Passion, and a Plan: Vera Therapeutics, Dr. Marshall Fordyce takes us from the bedside to the boardroom in his mission to treat autoimmune disease
|
Sep 24, 2021 |
|
A Promising Repurpose: Tenax Therapeutics Tests the Cancer Drug Imatinib in Pulmonary Arterial Hypertension
|
Sep 17, 2021 |
|
Medicenna Therapeutics: Reining in the Fire: Taming IL-2?
|
Sep 09, 2021 |
|
Immutep: No Longer Left Behind: LAG-3 Hits the Clinical (Late) Stage
|
Aug 27, 2021 |
|
Compugen Pioneering DNAM axis in cancer: TIGIT and PVRIG – Synergistic Checkpoints
|
Aug 20, 2021 |
|
HERVs and Nerves: Targeting the viral origins of neurodegenerative disease
|
Aug 13, 2021 |
|
Are iNKT cells the next frontier in cancer treatment?
|
Aug 06, 2021 |
|
Pixium Vision SA: An Eye Towards the Future: High Tech Treatment for Dry AMD
|
Jul 29, 2021 |
|
Arcellx: Plug and Play CAR-T: Modular Immunotherapy
|
Jul 23, 2021 |
|
A Time for Cocktails. Polytope: A Potential Treatment for Covid-19
|
Jul 12, 2021 |
|
Getting the Bugs out of Alzheimer’s: A New Therapeutic Approach
|
Jun 30, 2021 |
|
Switching it Up: Medigene Charts a New Course
|
Jun 28, 2021 |
|
Cancer Treatment Goes Viral Featuring: Dr. Matt Coffey, CEO Oncolytics Biotech
|
Jun 18, 2021 |
|
BiomX: A Real Phage-Turner
|
Jun 04, 2021 |
|
NK cell biology no longer stands for “Not Known”: Michael A. Caligiuri, M.D., Chief Medical Officer, and Co-founder of CytoImmune Therapeutics
|
May 12, 2021 |